Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE (NASDAQ:EVO) has signed a non-binding agreement with Sandoz AG for the potential sale of its Just - Evotec Biologics EU facility in Toulouse, France. The proposed transaction is valued at approximately $300 million in cash, with additional technology-related considerations including future development revenues, milestones, and product royalties.
Under the agreement, Sandoz would acquire full ownership of the Toulouse site, while Evotec maintains potential economic benefits through various revenue streams. The transaction is expected to enhance Evotec's revenue mix, profit margins, and capital efficiency. The deal's completion is subject to employee consultation processes, final agreements, and regulatory approvals.
Evotec SE (NASDAQ:EVO) ha firmato un accordo non vincolante con Sandoz AG per la possibile vendita della sua struttura Just - Evotec Biologics EU situata a Tolosa, Francia. L'operazione proposta ha un valore di circa 300 milioni di dollari in contanti, con ulteriori considerazioni tecnologiche che includono ricavi futuri da sviluppo, traguardi e royalty sui prodotti.
Secondo l'accordo, Sandoz acquisirebbe la piena propriet脿 del sito di Tolosa, mentre Evotec manterrebbe potenziali benefici economici attraverso diverse fonti di ricavo. Si prevede che la transazione migliorer脿 la composizione dei ricavi di Evotec, i margini di profitto e l'efficienza del capitale. Il completamento dell'accordo 猫 subordinato a processi di consultazione dei dipendenti, accordi finali e approvazioni regolatorie.
Evotec SE (NASDAQ:EVO) ha firmado un acuerdo no vinculante con Sandoz AG para la posible venta de su instalaci贸n Just - Evotec Biologics EU en Toulouse, Francia. La transacci贸n propuesta est谩 valorada en aproximadamente 300 millones de d贸lares en efectivo, con consideraciones adicionales relacionadas con la tecnolog铆a que incluyen ingresos futuros por desarrollo, hitos y regal铆as de productos.
Seg煤n el acuerdo, Sandoz adquirir铆a la propiedad total del sitio de Toulouse, mientras que Evotec mantendr铆a beneficios econ贸micos potenciales a trav茅s de diversas fuentes de ingresos. Se espera que la transacci贸n mejore la mezcla de ingresos de Evotec, los m谩rgenes de beneficio y la eficiencia del capital. La finalizaci贸n del acuerdo est谩 sujeta a procesos de consulta con empleados, acuerdos finales y aprobaciones regulatorias.
Evotec SE (NASDAQ:EVO)電� 頂勲瀾鞀� 韴措（歃堨棎 鞙勳箻頃� Just - Evotec Biologics EU 鞁滌劋鞚� 鞛犾灛鞝� 毵り皝鞚� 鞙勴暣 Sandoz AG鞕� 甑啀霠� 鞐嗠姅 瓿勳暯鞚� 觳搓舶頄堨姷雼堧嫟. 鞝滌晥霅� 瓯半灅 臧�旃橂姅 鞎� 3鞏� 雼煬 順勱笀鞚措┌, 頄ロ泟 臧滊皽 靾橃澋, 毵堨澕鞀ろ啢, 鞝滍拡 搿滌棿韹� 霌� 旮办垹 甏�霠� 於旉皜 瓿犽牑靷暛鞚� 韽暔霅╇媹雼�.
瓿勳暯鞐� 霐半澕 Sandoz電� 韴措（歃� 攵�歆�鞚� 鞕勳爠頃� 靻岇湢甓岇潉 鞚胳垬頃橂┌, Evotec鞚� 雼れ枒頃� 靾橃澋鞗� 韱淀暣 鞛犾灛鞝� 瓴届牅鞝� 鞚挫澋鞚� 鞙犾頃╇媹雼�. 鞚� 瓯半灅電� Evotec鞚� 靾橃澋 甑劚, 鞚挫澋毳�, 鞛愲掣 須湪靹膘潉 頄レ儊鞁滍偓 瓴�鞙茧 旮半寑霅╇媹雼�. 瓯半灅 鞕勲電� 歆侅洂 順戩潣 鞝堨皑, 斓滌 瓿勳暯 氚� 攴滌牅 鞀轨澑鞐� 霐半澕 雼澕歆戨媹雼�.
Evotec SE (NASDAQ:EVO) a sign茅 un accord non contraignant avec Sandoz AG pour la vente potentielle de son site Just - Evotec Biologics EU 脿 Toulouse, France. La transaction propos茅e est estim茅e 脿 environ 300 millions de dollars en esp猫ces, avec des consid茅rations technologiques suppl茅mentaires incluant des revenus futurs de d茅veloppement, des jalons et des redevances sur produits.
Selon l'accord, Sandoz acqu茅rirait la pleine propri茅t茅 du site de Toulouse, tandis qu'Evotec conserverait des b茅n茅fices 茅conomiques potentiels via diff茅rentes sources de revenus. Cette transaction devrait am茅liorer la r茅partition des revenus d'Evotec, ses marges b茅n茅ficiaires et son efficacit茅 capitalistique. La finalisation de l'accord est soumise aux consultations des employ茅s, aux accords finaux et aux approbations r茅glementaires.
Evotec SE (NASDAQ:EVO) hat eine unverbindliche Vereinbarung mit Sandoz AG 眉ber den potenziellen Verkauf seiner Just - Evotec Biologics EU-Anlage in Toulouse, Frankreich, unterzeichnet. Die vorgeschlagene Transaktion wird mit etwa 300 Millionen US-Dollar in bar bewertet, zus盲tzlich zu technologiebezogenen Aspekten wie zuk眉nftigen Entwicklungserl枚sen, Meilensteinen und Produktlizenzen.
Im Rahmen der Vereinbarung w眉rde Sandoz die vollst盲ndige Eigent眉merschaft des Standorts Toulouse 眉bernehmen, w盲hrend Evotec potenzielle wirtschaftliche Vorteile durch verschiedene Einnahmequellen beh盲lt. Die Transaktion soll Evotecs Umsatzmix, Gewinnmargen und Kapitaleffizienz verbessern. Der Abschluss des Deals h盲ngt von Mitarbeiterkonsultationen, finalen Vereinbarungen und beh枚rdlichen Genehmigungen ab.
- Significant cash consideration of $300 million
- Additional future revenue streams through development revenues, milestones, and royalties
- Expected improvement in revenue mix, profit margins, and capital efficiency
- Retention of economic upside potential while reducing operational costs
- Loss of direct control over the Toulouse biologics facility
- Transaction completion subject to multiple conditions and approvals
HAMBURG, DE / / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US
Under the proposed terms of the transaction, Sandoz would assume full ownership of the Just - Evotec Biologics Toulouse site, while Evotec would retain short-, mid-, and long-term economic upside through revenue, milestones and royalty optionality.
The planned deal would immediately improve Evotec's revenue mix, profit margins, and capital efficiency. Closing of the planned transaction remains subject to the completion of the relevant information and consultation processes with its employees and their representatives, final contractual agreements and to meeting regulatory requirements.
- End of the ad hoc release -
Contact: Volker Braun, EVP Head of Global Investor Relations & ESG, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49(0)151 1940 5058 (m), [email protected]
SOURCEW: Evotec SE
View the original on ACCESS Newswire
FAQ
What is the value of Evotec's potential sale of Just - Evotec Biologics Toulouse to Sandoz?
What will Evotec retain after selling the Toulouse facility to Sandoz?
How will the Sandoz deal affect Evotec's financial performance?
What conditions need to be met for the Evotec-Sandoz deal to close?
What type of agreement has been signed between Evotec and Sandoz?
